Last reviewed · How we verify
STIRIPENTOL oral administration
At a glance
| Generic name | STIRIPENTOL oral administration |
|---|---|
| Also known as | Multiple oral administration of stiripentol 1000 mg bis in die (BID) |
| Sponsor | Biocodex |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) (PHASE1)
- Pharmacokinetic Parameters of Stiripentol in Renal Impaired Patients and Matching Controls With Normal Renal Function (PHASE1)
- Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age (PHASE4)
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 (PHASE3)
- An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy (PHASE2)
- Fenfluramine for Adult Dravet Patients (PHASE3)
- A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome (PHASE3)
- Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STIRIPENTOL oral administration CI brief — competitive landscape report
- STIRIPENTOL oral administration updates RSS · CI watch RSS
- Biocodex portfolio CI